FACULTY
|
DR EILEEN SNEEDEN
Senior Director, Radiation Biophysics & Nuclear Oncology Liaison RayzeBio San Diego, USA Eileen Sneeden is Senior Director, Radiation Biophysics and Nuclear Oncology Liaison at RayzeBio, a Bristol Myers Squibb Company, with an innovation-leading position in actinium-based radiopharmaceutical therapeutics (RPTs) including RYZ101, a Phase 3 investigational, targeted RPT in a global Phase 3 study (ACTION-1) for treating patients with NETs. She is an accelerator instrumentationalist and radiation biophysicist by training (US Department of Energy/SLAC/Stanford Synchrotron scientist) and began thinking deeply about particle-biomatter interactions as a member of the atomic group building the first positron microscope at the University of Michigan, her alma mater. Eileen retooled in 2015 at UCLA Medical Physics, shifting her focus into a passion to do her part in advancing standard of care after unexpectedly losing someone dear to a disease. She began her industry career in clinical research and led global registrational studies at Medtronic Diabetes, representing the Clinical/Medical function on multiple core teams for product development and receiving the corporate Global Clinical Research Excellence Award as the Clinical Research Program Manager pioneering AI/Digital Platforms. A believer in a patient-first approach, Eileen joined RayzeBio in 2021 within 60 hours of the initial recruiter call, recognizing immediately the potential impact of targeted alpha therapy in the clinic. She remains passionate for patients (and their families) to win!
|
